Webinar

Advancing Pancreatic Cancer Drug Development Using Translational Models and Daraxonrasib Benchmarking Data

Wednesday July 29, 2026 | 10:30 AM EST and 2:00 PM EST

Pancreatic cancer remains one of the most difficult cancers to treat, with complex tumor biology, limited treatment options, and an urgent need for more predictive preclinical models. As drug development advances across KRAS-targeted therapies, antibody-drug conjugates (ADCs), immuno-oncology combinations, and other emerging approaches, researchers require model platforms that deliver both translational relevance and actionable data.

In this webinar, Crown Bioscience experts discuss how integrated in vitro and in vivo pancreatic cancer platforms support faster, more confident preclinical decision-making. The session highlights Crown Bioscience's broad pancreatic cancer portfolio, including 100+ models as well as daraxonrasib benchmarking data, patient-derived organoids, and in vivo systems that enable researchers to evaluate therapeutic response, investigate biomarkers, and prioritize development strategies.

Register Now

What You'll Learn:

• How Crown Bioscience's pancreatic cancer models with daraxonrasib data support benchmarking and translational strategy
  
  
• How pancreatic cancer organoid models enable rapid in vitro screening and responder analysis
  
  
• How in vivo pancreatic cancer models can be used to evaluate efficacy, response, and resistance
  
  
• Key considerations for selecting models for KRAS-targeted therapies, ADCs, and combination approaches
  
  
• How integrated in vitro and in vivo platforms support biomarker discovery and program decision-making

Register Now

Presenters

Rekha Pal PhD, Senior Director, Scientific Engagement, Crown Bioscience

Rekha is a Senior Director, Scientific Engagement at Crown Bioscience. She works to direct scientific engagement with pharmaceutical companies, academic scientists, and clients. She helps in decision making with goal of high scientific input in study design and model execution. Rekha is a trained cancer biologist with a focus on preclinical cancer therapeutics, stem cell biology, immune-oncology, cancer signaling, and tumor microenvironment. She earned her PhD in Biochemistry from Central Drug Research Institute, India. She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty.

Marten Hornsveld PhD, Principal Scientist, Crown Bioscience

Dr. Marten Hornsveld is a molecular and cell biologist that focuses on understanding and targeting molecular signal transduction in cancer. During his PhD program, he studied the role of PI3K-AKT and EGFR-KRAS signaling in breast cancer using a variety of mouse and cell based models. In his postdoctoral research he moved into the organoid technology field and worked on building representative organoid models for pancreatic cancer that include the tumor microenvironment. This resulted in the establishment of a novel close-to-patient mini-tumor model that can be employed for both basic research and pre-clinical studies. As a principal scientist at Crown Bioscience, he continues to work on building pre-clinical tumor models to facilitate rapid discovery of promising lead compounds in the oncology field.